Balchem Co. (NASDAQ:BCPC – Free Report) – Stock analysts at Sidoti Csr upped their Q1 2025 earnings per share (EPS) estimates for Balchem in a report released on Monday, October 28th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings of $1.19 per share for the quarter, up from their prior forecast of $1.16. The consensus estimate for Balchem’s current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2025 earnings at $1.21 EPS, Q3 2025 earnings at $1.22 EPS, FY2025 earnings at $4.82 EPS and Q1 2026 earnings at $1.27 EPS.
A number of other equities research analysts also recently commented on BCPC. HC Wainwright lifted their price target on shares of Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a research note on Monday.
Balchem Stock Down 0.2 %
BCPC opened at $168.88 on Wednesday. The business’s fifty day simple moving average is $171.75 and its 200 day simple moving average is $162.70. Balchem has a 52 week low of $114.97 and a 52 week high of $186.03. The firm has a market cap of $5.48 billion, a P/E ratio of 47.71, a PEG ratio of 5.43 and a beta of 0.65. The company has a quick ratio of 1.79, a current ratio of 2.83 and a debt-to-equity ratio of 0.26.
Institutional Investors Weigh In On Balchem
A number of institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Balchem in the 3rd quarter valued at $35,000. Bessemer Group Inc. boosted its holdings in Balchem by 568.9% in the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after acquiring an additional 256 shares during the last quarter. GAMMA Investing LLC grew its position in Balchem by 73.4% during the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 356 shares during the period. Blue Trust Inc. increased its stake in Balchem by 642.5% during the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock worth $148,000 after acquiring an additional 726 shares during the last quarter. Finally, TD Asset Management Inc purchased a new position in shares of Balchem in the 2nd quarter worth about $200,000. 87.91% of the stock is currently owned by hedge funds and other institutional investors.
About Balchem
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Stories
- Five stocks we like better than Balchem
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Want to Profit on the Downtrend? Downtrends, Explained.
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.
